title: C1858T Polymorphism of Protein Tyrosine Phosphatase Non-receptor Type 22 (PTPN22): an eligible target for prevention of type 1 diabetes?
abstract: In type 1 diabetes (T1D), several genetic factors are associated to β-cell autoimmunity onset and clinical progression. HLA-genes play a major role in susceptibility and initiation of β-cell autoimmunity, whereas non-HLA genes may influence the destruction rate. Areas covered: Our review focuses on the possible role of the PTPN22 C1858 T variant as a prognostic factor, given its influence on disease variability. Moreover, we present the potential role of C1858 T as a target for tertiary prevention trials and new therapeutic strategies, such as the LYP inhibitors. We used PubMed for literature research; key words were 'PTPN22', 'C1858 T polymorphism', 'lymphoid-specific tyrosine phosphatase' and 'type 1 diabetes'. We selected publications between 2000 and 2016. Expert commentary: Current data suggest that PTPN22 can be a promising target for therapeutic interventions and identification of at-risk subjects in autoimmune diseases such as T1D.
authors.affiliation: a Department of Pediatrics , 'G. D'Annunzio' University , Chieti , Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Prezioso
authors.affiliation: a Department of Pediatrics , 'G. D'Annunzio' University , Chieti , Italy.
authors.forename: Laura
authors.initials: L
authors.lastname: Comegna
authors.affiliation: a Department of Pediatrics , 'G. D'Annunzio' University , Chieti , Italy.
authors.forename: Concetta
authors.initials: C
authors.lastname: Di Giulio
authors.affiliation: a Department of Pediatrics , 'G. D'Annunzio' University , Chieti , Italy.
authors.forename: Simone
authors.initials: S
authors.lastname: Franchini
authors.affiliation: a Department of Pediatrics , 'G. D'Annunzio' University , Chieti , Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Chiarelli
authors.affiliation: a Department of Pediatrics , 'G. D'Annunzio' University , Chieti , Italy.
authors.forename: Annalisa
authors.initials: A
authors.lastname: Blasetti
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D058990:Molecular Targeted Therapy; D011110:Polymorphism, Genetic; D054596:Protein Tyrosine Phosphatase, Non-Receptor Type 22 / Q000037:antagonists & inhibitors / Q000235:genetics*
chemical_list: D007004:Hypoglycemic Agents; C516765:PTPN22 protein, human; D054596:Protein Tyrosine Phosphatase, Non-Receptor Type 22
keywords: Ptpn22; autoantibodies; autoimmune diseases; experimental pharmacology; lyp protein; polimorphism; prevention; type 1 diabetes